Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Vaccine for Prevention of Severe Covid-19 in Elderly
NCT04534803Phase 3Withdrawn
- Sponsor
- Harvard Medical School
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of bcg vaccine in coronavirus disease 2019 (COVID-19), sponsored by Harvard Medical School. Planned start Sep 2021; status: withdrawn.
02
Drugs
bcg vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04534803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534803.